×
About 405 results

ALLMedicine™ Antithrombin Deficiency Center

Research & Reviews  149 results

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
https://clinicaltrials.gov/ct2/show/NCT04918173

Aug 1st, 2022 - Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition.

Antithrombin Deficiency
http://emedicine.medscape.com/article/198573-overview

Jul 29th, 2022 - Practice Essentials Antithrombin (AT; also called heparin cofactor I; previously referred to as antithrombin III) is a 58-kDa molecule belonging to the serine protease inhibitor (serpin) superfamily that plays a central role in anticoagulation and...

Antithrombin Deficiency
https://emedicine.medscape.com/article/198573-print

Jul 29th, 2022 - Practice Essentials Antithrombin (AT; also called heparin cofactor I; previously referred to as antithrombin III) is a 58-kDa molecule belonging to the serine protease inhibitor (serpin) superfamily that plays a central role in anticoagulation and...

Antithrombin Deficiency
https://emedicine.medscape.com/article/198573-overview

Jul 29th, 2022 - Practice Essentials Antithrombin (AT; also called heparin cofactor I; previously referred to as antithrombin III) is a 58-kDa molecule belonging to the serine protease inhibitor (serpin) superfamily that plays a central role in anticoagulation and...

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antit...
https://doi.org/10.1213/ANE.0000000000006145
Anesthesia and Analgesia; Moront MG, Woodward MK et. al.

Jul 26th, 2022 - Antithrombin (AT) activity is reduced during cardiac operations with cardiopulmonary bypass (CPB), which is associated with adverse outcomes. Preoperative AT supplementation, to achieve >58% and <100% AT activity, may potentially reduce postoperat...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  8 results

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
https://clinicaltrials.gov/ct2/show/NCT04918173

Aug 1st, 2022 - Assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition.

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
https://clinicaltrials.gov/ct2/show/NCT00319228

May 11th, 2022 - This study will be a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment...

Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
https://clinicaltrials.gov/ct2/show/NCT04925167

Jul 9th, 2021 - Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However, many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc seriously affects the prognosis of patients. Argatroban is kind of...

Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation
https://clinicaltrials.gov/ct2/show/NCT04133844

Jun 4th, 2021 - Our hypothesis is that ECMO initiation is responsible for a severe decrease of antithrombin level in a high proportion of patients who develop heparin resistance.

"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"
https://clinicaltrials.gov/ct2/show/NCT02503267

Mar 27th, 2017 - Congenital disorders of glycosylation (CDG) are a family of inherited disorders caused by defects in the synthesis of glycans, glycoproteins or other glycoconjugates. Congenital disorders of glycosylation (CDG) are a family of inherited disorders ...

see more →

News  4 results

VTE Prophylaxis Warranted in Pregnant Women With Rare Thrombophilias
https://www.medscape.com/viewarticle/888208

Nov 9th, 2017 - NEW YORK (Reuters Health) - Women with some rare forms of thrombophilia can benefit from ante- or postpartum thrombosis prophylaxis, but those with more common types generally do not need preventive treatment, according to a new meta-analysis. Pre...

Purpuric lesion on the elbow
https://www.mdedge.com/ccjm/article/95725/dermatology/purpuric-lesion-elbow?channel=194
Naveen K. Voore, MD, Asima Rahman, MD, MRCGP, MRCOG et. al.

Apr 1st, 2012 - A 75-year-old man was admitted to the hospital with new-onset atrial fibrillation. He underwent rate control, and a heparin infusion was started.

New FDA Orphan Drugs: CDX-110, ATryn, ISIS 333611
https://www.medscape.com/viewarticle/567860

Dec 21st, 2007 - December 21, 2007 -- The US Food and Drug Administration (FDA) has granted orphan drug designation to CDX-110 for the treatment of glioblastoma multiforme, ATryn for the treatment of hereditary antithrombin deficiency, and ISIS 333611 for the trea...

Q.Are oral contraceptives safe for women with a thrombophilic defect?
https://www.mdedge.com/obgyn/article/62659/qare-oral-contraceptives-safe-women-thrombophilic-defect
Gerson Weiss, MD

Fast Track Women with a thrombophilic deficiency who used OCs developed VTE at a younger age than their non–OC-using counterparts A. No.

see more →